TL;DR: A 2026 study in BJPsych Open found that closely monitored antidepressant care improved quality of life and reduced societal costs in both PReDicT and usual-care groups, while the PReDicT algorithm added uncertain, country-dependent economic value. Key Findings Multinational trial data anchored the analysis: The economic evaluation followed 913 patients in France, Germany, the Netherlands, …
TL;DR: A 2026 systematic review and meta-analysis in Journal of Sleep Research found that agomelatine modestly improved subjective sleep quality versus placebo, but objective total sleep time did not significantly increase and somnolence reports were more frequent. Key Findings 25 RCTs: The review included 25 double-blind randomized controlled trials with 6,812 randomized participants. Subjective sleep …
TL;DR: A 2025 mouse study in eNeuro reported that inhaled cannabidiol reduced IDO and cGAS pathway activity and lowered pro-inflammatory cytokines in male 5XFAD Alzheimer’s model mice. Key Findings 5XFAD model: The study used male 5XFAD transgenic mice, a common amyloid-heavy Alzheimer’s disease model. Inhaled CBD: Cannabidiol was administered by inhalation rather than by oral …
TL;DR: A 2026 narrative review in Journal of Central Nervous System Disease found that glucagon-like peptide-1 receptor agonists have promising stroke-prevention and animal-model evidence, but human data do not yet support routine use as an acute ischemic stroke neuroprotective treatment. Key Findings Search through January 2026: The review covered preclinical stroke models, observational studies, randomized …
TL;DR: A 2026 study in Journal of Nanobiotechnology found that Angiopep-2-modified natural killer cell extracellular vesicles carried temozolomide across glioblastoma barriers, reduced mouse tumor bioluminescence, and extended median survival in an orthotopic GBM model. Key Findings 2.5-3.2x uptake: Angiopep-2 modification increased glioblastoma-cell uptake of NK extracellular vesicles compared with unmodified NK-EV. 2.8-3.5x BBB transport: Ang-NK-EV@TMZ …
TL;DR: A 2026 randomized study in The British Journal of Psychiatry found that the experimental 5-HT4 receptor agonist PF-04995274 did not mimic citalopram’s early emotional-bias effects in unmedicated depression, but it was linked with lower depression ratings and increased medial-frontal brain activation after about 1 week. Key Findings 90 randomized adults: The RESTAND study assigned …
TL;DR: A 2026 study in Psychopharmacology found that low oral THC doses did not meaningfully reduce most subjective or physiological responses when healthy adults retrieved memories of a prior social stress task. Key Findings Low-dose THC groups: Participants aged 18-35 were assigned to placebo, 5 mg THC, or 10 mg THC groups, with 12 people …
TL;DR: A 2026 exploratory study in Translational Psychiatry found blood DNA methylation changes after 25 mg psilocybin in detoxified alcohol use disorder patients, including findings near TLE4 and RASGRP4, but the small trial did not establish a definitive AUD biomarker. Key Findings 37 AUD patients: The methylation analysis used a randomized, double-blind psilocybin trial completed …
TL;DR: A 2026 study in Nature Communications used deep learning, yeast screening, and human brain organoids to identify talarozole and sertaconazole as preclinical candidates that rescued several SURF1-related Leigh syndrome cell and organoid phenotypes. Key Findings 2,250-drug yeast screen: Researchers screened a repurposable-drug library in a yeast model carrying a SURF1-homologue defect and selected top …
TL;DR: A 2026 preclinical study in the International Journal of Nanomedicine developed human umbilical cord mesenchymal stem cell membrane-coated PLGA nanoparticles to co-deliver doxorubicin and curcumin to glioblastoma models, improving tumor-cell uptake and mouse tumor suppression without proving human efficacy. Key Findings MSC membrane coating: Researchers coated PLGA nanoparticles with human umbilical cord mesenchymal stem …
